Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

6.560 +1.260 (+23.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abeona Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
Wednesday's session: top gainers and losers
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million. 
Via Benzinga
Exposures Product Safety
Abeona Stock Surges to 52-Week High: What's Behind The Move?
Abeona shares are trading higher on Wednesday on possible continued strength after the FDA announced approval for its gene therapy. 
Via Benzinga
Exposures Product Safety
Top stock movements in today's session.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Recap: Abeona Therapeutics Q3 Earnings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy
FDA approves Zevaskyn as the first cell-based gene therapy for RDEB wounds after strong results in pivotal and long-term studies. 
Via Benzinga
Exposures Product Safety
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease
ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, located across the U.S. with experience in cell and gene therapy. 
Via Stocktwits
Exposures Product Safety
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
ABEO Stock Earnings: Abeona Therapeutics Beats EPS for Q2 2024
ABEO stock results show that Abeona Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024
ABEO stock results show that Abeona Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Crude Oil Moves Higher; General Motors Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Dow Jumps Over 200 Points; US Services PMI Falls In April
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Affirm (AFRM) Stock Moving Today?
Affirm stock is falling on Tuesday as AFRM investors react to BNPL loan service One being added to Walmart's retail stores. 
Via InvestorPlace
US Stocks Higher; PepsiCo Posts Upbeat Earnings
Via Benzinga
FDA Rejects Approval Of Abeona Therapeutics' Skin Disorder Treatment, Shares Sink
Abeona Therapeutics' pz-cel gets the FDA's Complete Response Letter and Abeona's plans for fulfilling Chemistry Manufacturing and Controls requirements. 
Via Benzinga
Exposures Product Safety
Why Is Greenwave Technology Solutions (GWAV) Stock Down 47% Today?
Greenwave Technology Solutions stock is down on Tuesday as GWAV investors react to a registered direct offering and private placement. 
Via InvestorPlace
Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today?
Abeona Therapeutics stock is falling on Tuesday after the FDA sent it a CRL for more CMC data before it would approve Pz-cel. 
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Tuesday morning! 
Via InvestorPlace
Calix Reports Mixed Results, Joins Cadence Design Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023
ABEO stock results show that Abeona Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.